NCT07084909 - Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC | Biotech Hunter

Enrollment

286

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG

piflufolastat F 18

18F-DCFPyL is a fluorine-18 radiolabeled low molecular weight positron emission tomography (PET) tracer that binds to the extracellular domain of prostate-specific membrane antigen (PSMA) with high affinity.

Trial Locations (2)

63130

RECRUITING

Washington University in St. Louis, St Louis

68130

RECRUITING

XCancer, Omaha